Kelly, K., Johnson, M. L., Mahalingam, D., Liu, S. V., Uronis, H. E., Wu, C., … Duska, L. R. (2018). A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors. In Journal of Clinical Oncology (Vol. 36, pp. TPS2617–TPS2617). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.tps2617

Kelly, Karen, Melissa Lynne Johnson, Devalingam Mahalingam, Stephen V. Liu, Hope Elizabeth Uronis, Christina Wu, Laura Carter, et al. “A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors.” In Journal of Clinical Oncology, 36:TPS2617–TPS2617. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps2617.

Kelly K, Johnson ML, Mahalingam D, Liu SV, Uronis HE, Wu C, et al. A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS2617–TPS2617.

Kelly, Karen, et al. “A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. TPS2617–TPS2617. Crossref, doi:10.1200/jco.2018.36.15_suppl.tps2617.

Kelly K, Johnson ML, Mahalingam D, Liu SV, Uronis HE, Wu C, Carter L, Hu X, Weems GA, Wilkins HJ, Duska LR. A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS2617–TPS2617.